Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Abvc Biopharma (ABVC) EBT (2016 - 2025)

Historic EBT for Abvc Biopharma (ABVC) over the last 14 years, with Q3 2025 value amounting to -$1.3 million.

  • Abvc Biopharma's EBT fell 16422.9% to -$1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.3 million, marking a year-over-year decrease of 468.55%. This contributed to the annual value of -$5.4 million for FY2024, which is 3308.8% up from last year.
  • Per Abvc Biopharma's latest filing, its EBT stood at -$1.3 million for Q3 2025, which was down 16422.9% from -$2.3 million recorded in Q2 2025.
  • Abvc Biopharma's EBT's 5-year high stood at -$487076.0 during Q3 2024, with a 5-year trough of -$6.2 million in Q1 2022.
  • For the 5-year period, Abvc Biopharma's EBT averaged around -$2.4 million, with its median value being -$2.0 million (2022).
  • Its EBT has fluctuated over the past 5 years, first plummeted by 39540.63% in 2022, then skyrocketed by 8554.28% in 2024.
  • Over the past 5 years, Abvc Biopharma's EBT (Quarter) stood at -$5.9 million in 2021, then surged by 39.93% to -$3.5 million in 2022, then surged by 85.16% to -$524999.0 in 2023, then tumbled by 51.72% to -$796527.0 in 2024, then plummeted by 61.58% to -$1.3 million in 2025.
  • Its EBT stands at -$1.3 million for Q3 2025, versus -$2.3 million for Q2 2025 and -$944190.0 for Q1 2025.